Global Diabetic Retinopathy Treatment Market to Reach $11.6 Billion by 2030
The global market for Diabetic Retinopathy Treatment estimated at US$7.8 Billion in the year 2022, is projected to reach a revised size of US$11.6 Billion by 2030, growing at a CAGR of 5% over the analysis period 2022-2030. Non-Proliferative Diabetic Retinopathy, one of the segments analyzed in the report, is projected to record 5.6% CAGR and reach US$7.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Proliferative Diabetic Retinopathy segment is readjusted to a revised 4% CAGR for the next 8-year period.The U.S. Market is Estimated at $2.1 Billion, While China is Forecast to Grow at 8.5% CAGR
The Diabetic Retinopathy Treatment market in the U.S. is estimated at US$2.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 8.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 4.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.Select Competitors (Total 42 Featured) -
- Alimera Sciences, Inc.
- Allergan PLC
- Ampio Pharmaceuticals, Inc.
- BCN Peptides S.A.
- Genentech, Inc.
- Glycadia, Inc.
- Kowa Co., Ltd.
- Novartis International AG
- Regeneron Pharmaceuticals, Inc.
- Sirnaomics, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alimera Sciences, Inc.
- Allergan PLC
- Ampio Pharmaceuticals, Inc.
- BCN Peptides S.A.
- Genentech, Inc.
- Glycadia, Inc.
- Kowa Co., Ltd.
- Novartis International AG
- Regeneron Pharmaceuticals, Inc.
- Sirnaomics, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 273 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 7.8 Billion |
Forecasted Market Value ( USD | $ 11.6 Billion |
Compound Annual Growth Rate | 5.1% |
Regions Covered | Global |